| 引用本文: | 杨群,李晓辉,胡海英,张锴,廖红德,姚航宇,吴邵杰,张淑慧.基于理化性质的枸橼酸托法替布处方前研究[J].中国现代应用药学,2022,39(2):174-180. |
| YANG Qun,LI Xiaohui,HU Haiying,ZHANG Kai,LIAO Hongde,YAO Hangyu,WU Shaojie,ZHANG Shuhui.Pre-prescription Study Based on Physical and Chemical Properties of Tofacitinib Citrate[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(2):174-180. |
|
| |
|
|
| 本文已被：浏览 1669次 下载 1010次 |
码上扫一扫！ |
|
|
| 基于理化性质的枸橼酸托法替布处方前研究 |
|
杨群1, 李晓辉1, 胡海英2, 张锴3, 廖红德1, 姚航宇1, 吴邵杰1, 张淑慧1
|
|
1.绍兴文理学院元培学院, 浙江 绍兴 312000;2.绍兴市越城区东湖街道社区卫生服务中心, 浙江 绍兴 312000;3.绍兴震元中药饮片有限公司, 浙江 绍兴 312000
|
|
| 摘要: |
| 目的 考察枸橼酸托法替布理化性质，为其制剂处方、工艺设计、包装和储藏等提供理论依据。方法 采用HPLC测定药物在不同pH缓冲液及水中的平衡溶解度、脂水分配系数(P)及润湿性；对药物进行影响因素试验；测定药物的粒度、粒度分布、红外光谱(FTIR)、X-射线衍射图谱(XRD)、差示扫描量热图谱(DSC)和扫描电镜图谱(SEM)。结果 枸橼酸托法替布在pH 1.0~8.0的缓冲液及水中的平衡溶解度为0.183 4~22.594 1 mg·mL-1，属高溶解性药物，其中在pH 1.0缓冲液中的平衡溶解度最大；在上述各介质中，lgP为-1.34~1.28，属低渗透性药物，其中在pH 3.6缓冲液中的lgP最大；在上述各介质中，接触角均<90°，均易于被润湿；枸橼酸托法替布在高温、高湿及强光照射下均较为稳定；平均粒径为(29.85±0.17)µm；XRD、DSC及SEM结果均表明枸橼酸托法替布为结晶性药物，熔点为210 ℃；FTIR结果表明，枸橼酸托法替布在3 375.44，3 134.51，1 732.54，1 711.78，1 625.24，1 551.03，1 529.52，1 473.76，1 448.28，1 409.48，1 348.17，1 213.59，1 170.22，1 115.37，1 077.68，1 023.87，916.97，846.38，775.66，741.84，703.42，603.15，444.07 cm-1有较强的红外特征峰。结论 枸橼酸托法替布为BCSⅢ类药物，宜设计成胃内滞留型给药系统，有利于药物在上消化道溶解与吸收，以提高生物利用度；本研究使用的枸橼酸托法替布为稳定的结晶性药物，可满足一般制剂生产、包装、贮藏等要求。 |
| 关键词: 枸橼酸托法替布 平衡溶解度 脂水分配系数 影响因素试验 接触角 差示扫描量热法 扫描电镜法 X-射线衍射法 红外光谱法 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.02.006 |
| 分类号:R943 |
| 基金项目:绍兴市科技计划项目(2018C30009)；国家级大学生创新创业训练计划项目(201910349006，202110349014)；浙江省大学生科技创新活动计划暨新苗人才计划项目(2018R432017)；浙江省十二届大学生生命科学竞赛三等奖项目(35787) |
|
| Pre-prescription Study Based on Physical and Chemical Properties of Tofacitinib Citrate |
|
YANG Qun1, LI Xiaohui1, HU Haiying2, ZHANG Kai3, LIAO Hongde1, YAO Hangyu1, WU Shaojie1, ZHANG Shuhui1
|
|
1.Shaoxing University Yuanpei College, Shaoxing 312000, China;2.Community Health Service Center of Donghu Street, Yuecheng District, Shaoxing City, Shaoxing 312000, China;3.Shaoxing Zhenyuan Herbal Pieces Co., Ltd., Shaoxing 312000, China
|
| Abstract: |
| OBJECTIVE To investigate the physical and chemical properties of tofacitinib citrate, to provide theoretical basis for its formulation, process design, packaging and storage, etc. METHODS HPLC was used to determine the equilibrium solubility, lipid-water partition coefficient(P) and wettability of the drug in different pH buffers and water. The influencing factor trials of the drug were tested. The particle size, particle size distribution, infrared spectroscopy(FTIR), X-ray diffraction(XRD), differential scanning calorimetry(DSC) and scanning electron microscope(SEM) of the drug were determined. RESULTS The equilibrium solubility of tofacitinib citrate was 0.183 4-22.594 1 mg·mL-1 in pH 1.0-8.0 buffer and water, which was a highly soluble drug. Among them, the equilibrium solubility in pH 1.0 buffers was the largest. The lgP was -1.34-1.28 in the above medium, belongs to a low permeability drug. Among them, the lgP in pH 3.6 buffer was the largest. The contact angles in the above medium were all <90°, and they were all easily wetted by these media. Tofacitinib citrate was stable under high temperature, high humidity and strong light irradiation. The average particle size of tofacitinib citrate was (29.85±0.17)µm. XRD, DSC and SEM results all showed that tofacitinib citrate was a crystalline drug, the melting point was 210 ℃. FTIR results showed that tofacitinib citrate had strong infrared characteristic peaks at 3 375.44, 3 134.51, 1 732.54, 1 711.78, 1 625.24, 1 551.03, 1 529.52, 1 473.76, 1 448.28, 1 409.48, 1 348.17, 1 213.59, 1 170.22, 1 115.37, 1 077.68, 1 023.87, 916.97, 846.38, 775.66, 741.84, 703.42, 603.15, 444.07 cm-1, etc. CONCLUSION Tofacitinib citrate is a BCS class III drug. It is suitable to be designed into a gastric retention type drug delivery system, which is beneficial to the dissolution and absorption of the drug in the upper digestive tract to improve the bioavailability. The tofacitinib citrate used in this experiment is a stable crystalline drug that can meet the requirements of general preparation production, packaging, and storage. |
| Key words: tofacitinib citrate equilibrium solubility lipid-water partition coefficient influencing factor test contact angle differential scanning calorimetry scanning electron microscope X-ray diffraction infrared spectroscopy |
|
|
|
|
